# Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity

- Link: https://www.thailand-business-news.com/pr-news/harbour-biomed-announces-nmpa-acceptance-of-ind-application-for-its-first-ai-enabled-drug-candidate-let003-for-the-treatment-of-overweight-or-obesity
- Published: 2026-11-19T07:01:00+07:00
- Author: PR Newswire

|   |

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 19, 2026 /PRNewswire/—
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company 
committed to the discovery and development of novel antibody therapeutics in immunology,
oncology and other areas, today announced that the National Medical Products Administration(
NMPA) of China has accepted the Investigational New Drug (IND) application for LET003,
its first next-generation ACVR2A/2B-targeting monoclonal antibody developed using
the Hu-mAtrIx™ AI platform, for the treatment of overweight or obesity.

Obesity is a chronic, complex disease associated with an increased risk of numerous
serious health conditions, including type 2 diabetes, cardiovascular disease and
certain cancers. While GLP-1-based therapies have transformed obesity management
by enabling substantial weight loss, the accompanying loss of lean mass remains 
a major challenge in optimizing body composition and long-term treatment outcomes.
Targeting activin receptors ACVR2A and ACVR2B, which play key roles in regulating
muscle and fat homeostasis, represents a promising therapeutic approach to enhancing
fat reduction while preserving or improving lean mass, particularly in combination
with existing weight-loss therapies.

LET003 is Harbour BioMed’s first AI-enabled drug candidate, designed as a dual ACVR2A/
ACVR2B blocker to target these receptors. In preclinical studies, LET003 exhibited
superior pharmacokinetic characteristics compared to multiple competitor molecules.
When combined with semaglutide, LET003 significantly enhanced fat reduction while
effectively preserving lean mass. In addition, LET003 achieved lean mass-promoting
effects at lower dose level comparable to bimagrumab at higher dose level, highlighting
its potential to become a best-in-class therapy for overweight or obesity treatment.

"NMPA’s acceptance of the IND application for LET003 marks a significant milestone
for Harbour BioMed. LET003 leads the exciting progress in our obesity portfolio 
in addition to being our first AI-enabled candidate developed using our proprietary
Hu-mAtrIx™ platform," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour
BioMed. "We look forward to advancing LET003 through clinical development and further
realizing the potential of our AI-enabled drug discovery capabilities to address
significant unmet medical needs."

"Obesity treatment is evolving beyond weight reduction alone toward improving body
composition and achieving more sustainable health outcomes," said Dr. Bob Zhang,
President of the Metabolic Disease Franchise at Harbour BioMed. "By targeting ACVR2A
and ACVR2B, LET003 is designed to address an important challenge in overweight or
obesity management: preserving or improving lean mass while enhancing fat reduction.
We believe LET003 has the potential to offer a differentiated therapeutic approach
and look forward to evaluating its potential in clinical development."

**About LET003**

LET003 is a potential best-in-class next-generation monoclonal antibody targeting
activin receptors ACVR2A and ACVR2B. ACVR2A and ACVR2B play critical roles in regulating
muscle-fat metabolic homeostasis. Extensive preclinical and clinical studies have
demonstrated that combining receptor-blocking antibodies targeting ACVR2A/2B with
GLP-1-based weight loss therapies can further reduce body fat while effectively 
mitigating lean mass loss. LET003 is the first ACVR2A/2B dual-target blocking antibody
developed using the Hu-mAtrIx™ artificial intelligence platform. It has demonstrated
superior pharmacokinetic properties compared with several competing molecules and,
in preclinical animal models, has shown enhanced fat reduction and lean mass preservation
effects when used in combination with GLP-1 therapies.

**About Harbour BioMed**

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to 
the discovery and development of novel antibody therapeutics in immunology, oncology
and other areas. The Company is building a robust portfolio and differentiated pipeline
through internal R&D capability, strategic global collaborations in co-discovery
and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice^(®), generates fully 
human monoclonal antibodies in both the conventional two heavy and two light chain(
H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies,
the HCAb-based immune cell engagers (HBICE^(®)) bispecific antibody technology enables
tumor-killing effects that traditional combination therapies cannot achieve. The
HCAb-based Antibody Plus technology (HCAb PLUS^(TM)) provides comprehensive modality
solutions for the development of innovative multi-specific medicines in different
disease areas. Additionally, building upon the Harbour Mice^(®) platform, Harbour
BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-
mAtrIx^(TM) AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice^(®), HBICE^(®), HCAb PLUS^(TM), a single B-cell cloning
platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive
antibody discovery engine for developing next-generation therapeutic antibodies.
For more information, please visit [www.harbourbiomed.com](http://www.harbourbiomed.com/).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity ](https://en.prnasia.com/story/archive/5101188_CN01188_0?rand=184833)
